MRO Magazine

Research and Markets: Investigation Report on China’s Rituximab Market, 2010-2019


June 11, 2015
By Business Wire News

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/bhpvvl/investigation) has announced the addition of the “Investigation Report on China’s Rituximab Market, 2010-2019” report to their offering.

Rituximab (trade name is Rituxan by Roche) was a human- mouse chimeric anti- CD20 monoclonal antibody approved by FDA to treat tumor in 1997. The treatment range of Rituximab extends from B- cell malignant tumors to rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura and such autoimmune diseases. In 2014, the sales revenue of Rituxan exceeded USD 8 billion.

In China, the incidence of non- Hodgkin lymphoma fast rises from 20/1 million at the end of 20 century to 70/1 million nowadays. Autoimmune diseases can harm the central nervous system and organs such as the lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be life threatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such incidence is high enough to attract people’s attention.

By the second quarter of 2015, there is no Rituximab produced by Chinese domestic enterprise on the market. The market is wholly occupied by products of Roche. Early 2014, monoclonal antibody drug “recombinant human- mouse chimeric anti- CD20 monoclonal antibody injection” produced by Hisun was approved clinical. It is generic drug of Rituximab of Roche. Five manufacturers in China have reported clinical use of rituximab generic drug. It is estimated that more generic drugs will go on the market in the next few years. According to the author’s investigation on certain sample hospitals in China, the CAGR of sales value of rituximab surpassed 30% from 2005 to 2014. Rituximab is expected to have huge room to grow in future Chinese market.

Companies Mentioned:

– Hoffmann-La Roche, Inc.

– Roche Diagnostics

– Shanghai Roche Pharmaceutical Co., Ltd.

– Shanghai Hongguang Chemicals

For more information visit http://www.researchandmarkets.com/research/bhpvvl/investigation

About Research and Markets

Research and Markets is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Chemicals